Ignite Creation Date:
2024-05-05 @ 4:56 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00351611
Status:
COMPLETED
Last Update Posted:
2021-04-13
First Post:
2006-07-11
Brief Title:
Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo
Sponsor:
Pfizers Upjohn has merged with Mylan to form Viatris Inc
Organization:
Pfizer
Study Overview
Official Title:
PROSPECTIVE RANDOMIZED 12-WEEK CONTROLLED STUDY OF VISUAL FIELD CHANGE IN SUBJECTS WITH PARTIAL SEIZURES RECEIVING PREGABALIN OR PLACEBO
Status:
COMPLETED
Status Verified Date:
2021-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with partial seizures currently taking 1-3 antiepileptic medications will have a 5050 chance to receive Lyrica 300 mg per day or placebo no active ingredients added on to their current medications for 3 months Neither the study doctor nor the patient will know the medication assignment Vision testing will be performed prior to receiving the study treatment and at the end of the study to see if there are any changes
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2009-014269-25 | EUDRACT_NUMBER | None | None |